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1. Introduction 
Fibrosis, also known as scarring, sclerosis or cirrhosis, is characterised by excessive 
accumulation of extracellular matrix (ECM) proteins leading to tissue contraction, 
disruption of tissue architecture and eventually chronic organ failure (Wynn, 2007; Xu et al., 
2007). Research and development of anti-fibrotic drugs are generally based on two distinct 
but interactive strategies, with one based on mechanism studies and another based on 
exploring efficacy. In principle, the mechanism-based strategy begins with identification of 
molecular targets through mechanistic studies, and then development of inhibitors or 
enhancers targeting the molecules. On the other hand, efficacy-based strategy starts with 
screening drug candidates in disease models to identify activities and efficacy, with less 
reliance on analysis of mechanisms of action. There are certain limitations in both the 
mechanism-based strategy and the efficacy-based strategy, which largely account for the 
lack of success in development of anti-fibrotic drugs. The former is often associated with 
identification of multiple molecular targets impeding development of a single drug that 
tackles multiple targets, while the latter is often hampered by establishment of apt models 
ideal for efficacy-driven drug screens. 
Efficacy-based strategy has been employed in development of both traditional and modern 
medicines. In the context of traditional medicine, the knowledge about efficacy of a given 
drug is largely derived from a trial-and-error process, namely by assessing patients’ 
response upon treatment with natural drug candidates. However, in modern medicine, it is 
impossible to directly test any new drugs in patients. Solid scientific evidence on efficacy 
and safety of a given drug in experimental models is required prior to clinical trials. 
Understandably, quality of these models would determine the specificity and efficiency of 
the tested drug. 
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In vivo models are invaluable research tools but not without its limitation, especially in the 
development of drugs targeting fibrosis given the complex aetiologies and inflammatory 
processes involved in this pathological condition. In particular, drug leads displaying 
effectiveness in in vivo models of fibrosis may stem from (i) inhibition of the primary 
aetiological factors, (ii) inhibition of inflammation, a common inciting factor of fibrosis, (iii) 
inhibition of fibrosis per se, or (iv) a net effect of any combinations of the aforementioned. 
For the initial development of drugs with specific anti-fibrotic effects independent of anti-
inflammatory actions and any specific aetiological factors, in vitro models of fibrosis appear 
to be more appropriate. Our laboratory recently reported transforming growth factor-1 
(TGF-1)-induced inflammation-free in vitro models of fibrosis in mesenchymal cells, 
featuring 2-dimentional (2D) ECM protein accumulation reflecting net collagen 
accumulation, and 3-dimentional (3D) nodular formation following ECM protein-induced 
disruption of cell monolayer, which can both be objectively quantified. By coating specific 
matrix on 96-well plates, which determines the 2D or 3D nature of the models, we are able 
to quantify readouts more reliably, permitting high-throughput screening of compounds 
with anti-fibrotic activities (Xu et al., 2007). 
In contrast to the lack of “anti-fibrotics” in Western medicine clinics, there is accumulating 
evidence suggesting anti-fibrotic effects of Chinese materia medicas (CMMs), i.e., medicinal 
materials used in traditional Chinese medicine (TCM) (Hu et al., 2007). However, most of 
these conclusions were drawn from animal models or patients and hence it was not clear 
whether the reported efficacy of those CMMs was secondary to inhibition of aetiological 
factors or inflammation, or whether they exerted genuine anti-fibrotic activities (Hu et al., 
2009). We hypothesised that at least some of the “anti-fibrotic” herbal derivatives reported 
in the literature are indeed anti-fibrotic by antagonising TGF-1-specific pro-fibrotic 
pathways or common pathways of fibrosis. By employing the 2D in vitro model (Xu et al., 
2007), we tested the anti-fibrotic activity of 21 CMM-derived compounds, 11 methanolic 
extracts of single CMMs and 27 formulae that contained two or more CMMs as mixtures, 
and found that five compounds, three single CMM extracts and 16 formulae had in vitro 
anti-fibrotic activities (Hu et al., 2009). Among the five CMM-derived compounds, three 
flavonoids (quercetin, baicalin and baicalein) showed similar dose-dependent in vitro anti-
fibrotic activities while two non-flavonoids (salvianolic acid B and emodin) showed varied 
in vitro anti-fibrotic activities with poor dose dependency. Among the three CMM extracts 
showing significant in vitro anti-fibrotic activities, Huangqin (root of Scutellaria baicalensis 
Georgi) is rich in baicalin and baicalein, Danshen (root of Salvia miltiorrhiza Bunge) is rich in 
salvianolic acid B and Dahuang (root of Rheum palmatum L.) is rich in emodin. Among the 16 
herbal formulae with in vitro anti-fibrotic effects, eight contained neither Huangqin, 
Danshen nor Dahuang, while the remaining eight contained at least one of the three CMMs 
(Hu et al., 2009). 
Following successful identification of in vitro anti-fibrotic activities in herbal entities, we 
have extended our work to focus on TCM knowledge-based discovery of novel anti-fibrotic 
drug leads from natural sources, especially CMMs. In TCM, fibrosis is diagnosed as a kind 
of “Jie Zheng” which means “lump or clot”. Based on this concept, two senior TCM 
practitioners were invited to choose a collection of 27 CMMs, including 26 medicinal plant 
parts and one medicinal fungus, which they would consider using in patients with fibrotic 
diseases. Based on the traditional categories of CMMs, the 27 CMMs fall into three 
functional subgroups, namely “Huo Xue Hua Yu” (“promoting the circulation and resolving 
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the clot”), “Hua Tan” (“resolving the sputum”) and “Bu Xu” (“tonifying the deficiency”), 
where “clot” and “sputum” in TCM do not mean the same as the terms in Western 
medicine. In addition to the 27 CMMs, Chuanwutou, an unprocessed herb with well-known 
toxic effects, was also tested to serve as a control for cytotoxic effects, if any. In fact, owing to 
its strong “Qu Feng Shi” (“dispelling the wind and damp” or anti-rheumatic function) 
property, Chuanwutou is rather commonly prescribed to patients with diseases complicated 
by fibrosis, although only processed Chuanwutou is allowed for clinical use. 
The aim of this project was to examine the in vitro anti-fibrotic and pro-fibrotic activities of 
these 28 CMMs (Table 1) and herein we report that eight CMMs (Baibeiyegen, Liedang, 
Gusuibu, Jixueteng, Lingzhi, Meiguiqie, Moyao and Shiliuhua) have in vitro anti-fibrotic 
activities while three (Chuanwutou, Dangshen and Yimucao) have pro-fibrotic activities. 
2. Materials and methods 
2.1 CMMs and extraction methods 
Liedang was authenticated according to the criteria described in Jilin Zhongcaoyao 
(Changchun TCM College Revolutionary Committee (Ed.), (June 1970), Jilin Chinese Herbal 
Medicine, Jilin People’s Press, Changchun, China) and all other CMMs were authenticated 
according to Chinese Pharmacopeia (2005 Edition). Voucher specimens were deposited at 
Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China. 
Individual CMM was grounded into fine powder, from which 85 g was precisely weighed 
out and added to 600 ml of 80% ethanol. The mixtures were boiled for 2 h and filtrated, after 
which the residual ethanol was evaporated. Ethanolic extracts were then concentrated and 
dried in an oven, and were stored at room temperature before use. For experimental 
purpose, ethanolic extracts were reconstituted in dimethyl sulfoxide (DMSO, Sigma-Aldrich 
Company Ltd., Dorset, UK) and were stored in freezer at -20 °C until use. 
2.2 TGF-1, Alk5 inhibitor and PPAR antagonists 
Human TGF-1 in lyophilised powder form (R&D Systems Europe Ltd., Abingdon, UK) 
was reconstituted in filter-sterilised buffer consisting of 1 mg/ml bovine serum albumin in 4 
mM HCl, to a final concentration of 10 µg/ml and kept frozen at -80 ºC before experiments. 
IN-1130, a selective inhibitor of TGF- type I receptor (Alk5), was a kind gift from Dr Dae 
Kee Kim, Ewha Women’s University, Korea, and was used as a positive control for in vitro 
anti-fibrotic activity (Moon et al., 2006). Peroxisome proliferator-activated receptor (PPAR) 
antagonists, including PPAR antagonist GW6471 (Xu et al., 2002), PPAR/ antagonist 
GSK0660 (Shearer et al., 2008) and PPAR antagonist T0070907 (Lee et al., 2002) were 
purchased from Sigma-Aldrich. 
2.3 Cell culture, TGF-1-induced in vitro models of fibrosis and related assays 
A normal rat kidney fibroblast cell line (NRK-49F) was purchased from European Collection 
of Cell Cultures (ECACC, Health Protection Agency, Salisbury, UK). The cells were 
maintained in Dulbecco's Modified Eagle Medium (DMEM, PAA Laboratories Ltd., 
Somerset, UK) supplemented with 100 U/ml of penicillin G (PAA), 100 μg/ml of 
streptomycin (PAA), 0.25 μg/ml of amphotericin B (Invitrogen Ltd., Paisley, UK) and 5% 
foetal calf serum (FCS, Sigma-Aldrich), in Falcon tissue culture flasks (Marathon Laboratory 
supplies, London, UK), and incubated at 37 °C and 5% CO2. During routine maintenance, 
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Functional group Pinyin name Part, Latin name and 
authority  
Authenticator Extraction 
yield (%) 
Voucher 
number 
“Bu Xu” Baibeiyegen Dried roots of Mallotus 
apelta (Lour.) Muell.-Arg.
SJS* 21 B012081 
Liedang Dried whole plants of 
Orobanche coerulescens 
Steph. 
SJS 28.5 C013081 
Dangshen Dried roots of Codonopsis 
pilosula (Franch.) Nannf. 
SJS 58.7 D001081 
Gancao Dried roots and rhizomes 
of Glycyrrhiza uralensis 
Fisch. 
SJS 81.7 G010081 
Roucongrong Dried fleshy stem with 
scales of Cistanche 
deserticola Y. C. Ma 
SJS 82.2 R002081 
Yinyanghuo Dried rootless plants of 
Epimedium brevicornum 
Maxim. 
SJS 42.1 Y006081 
“Bu Xu” &  
“Hua Tan” 
Lingzhi Dried mushroom of 
Ganoderma lucidum (Leyss. 
Ex Fr.) Karst. 
SJS 8.33 L003081 
“Hua Tan” Baiguo Dried ripe seeds of Ginkgo 
biloba L. 
HXR** 7.9 B013041 
Jiegeng Dried roots of Platycodon 
grandiflorum (Jacq.) A. DC.
SJS 12.3 J009081 
Meiguiqie Dried flowers of Hibiseus 
sabdariffa L. 
SJS 37.6 M004081 
Tiannanxing Dried tuberous roots of 
Arisaema erubescens (Wall.) 
Schott. 
SJS 2.34 T001081 
“Hua Tan” and 
“Huo Xue Hua 
Yu” 
Yinxingye Dried leaves of Ginkgo 
bilobla L. 
SJS 65 Y009081 
 “Huo Xue Hua 
Yu“ & “Qing Re 
Jie Du”*** 
Baihuasheshecao Dried plants of 
Oldenlandia diffusa (Willd.) 
Roxb. 
HXR 18 B010041 
“Huo Xue Hua 
Yu” 
Ezhu Dried rhizomes of 
Curcuma kwangsiensis S. G. 
Lee et C. F. Liang 
HXR 60.1 E001041 
Gusuibu Dried rhizomes of 
Drynaria fortunei (Kunze) 
J. Sm. 
SJS 27 G007081 
Jixueteng Dried stem of Spatholobus 
suberectus Dunn 
SJS 33.9 J001081 
Maqianzi Dried ripe seeds of 
Strychnos nux-vomica L. 
SJS 7.7 M003081 
Moyao Dried resin of Commiphora 
myrrha Engl. 
SJS 33.7 M002081 
Niuxi Dried roots of Achyranthes 
bidentata Bl. 
SJS 9.9 N002081 
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Functional group Pinyin name Part, Latin name and 
authority  
Authenticator Extraction 
yield (%) 
Voucher 
number 
Ruxiang Dried oleogum resin of
Boswellia carterii Birdw.
SJS 60.6 R001081 
Sanleng Dried tuberous roots of
Sparganium stoloniferum 
Buch.–Ham.
SJS 25.1 S003081 
Sheputaogen Dried roots of Ampelopsis 
(Miq.) W. T. Wang
SJS 14 S011081 
Shiliuhua Dried flowers of Punica 
granatum L. 
SJS 88 S012081 
Taoren Dried ripe seeds of Prunus 
persica (L.) Batsch.
SJS 35.6 T004081 
Yanhusuo Dried tuberous roots of
Corydalis yanhusuo W. T. 
Wang
HXR 69.5 Y010041 
Yimucao Dried rootless plants of
Leonurus japonicus Houtt.
SJS 12.8 Y005081 
Zhenzhumei Dried bark of the stems of
Sorbaria sorbifolia (L.) A. 
Brown.
SJS 33.1 Z004081 
“Qu Feng Shi” Chuanwutou Dried main roots of
Aconitum carmichaeli 
Debx.
SJS 18.2 C005081 
Table 1. Functional groups, species names and parts, authenticators, extraction yield and 
voucher numbers of the 28 test materials. * SJS: Shi Jian Sa, Tong De Chinese Materia Medica 
Co. Ltd., Anguo, Hebei, China; ** HXR: He Xi Rong, Institute of Chinese Materia Medica, 
China Academy of Chinese Medical Sciences, Beijing, China; *** “Qing Re Jie Du” means 
“clearing heat and detoxifying”. 
NRK-49F cells were sub-cultured before they became confluent to prevent transformation. 
The 2D model was employed for experiments in this project. Cells were seeded in collagen 
type I-coated 96-well plates (BD Biosciences, Oxford, UK) at a density of 1104 cells per well 
in 200 µl DMEM supplemented with 2.5% FCS and 2.5% Nu-SerumTM V serum replacements 
(NU, BD Biosciences). After three days, the medium was changed to serum-free DMEM 
supplemented with 1% insulin-transferrin-selenium liquid media supplement (ITS, Sigma-
Aldrich) for four days, and then changed to fresh ITS-supplemented serum-free medium 
containing 5 ng/ml TGF-1 in the presence of different concentrations of herbal extracts or a 
vehicle control (an equal volume of DMSO) for 48 h. In all the experiments, 1 µM IN-1130 
was used as a positive control for anti-fibrotic activities. For initial screening, the 
concentrations of CMM extracts tested were 10, 20, 40, 80, 160 and 200 µg/ml, 3-6 wells per 
group, and the screening was repeated at least twice. For follow-up confirmation studies, 
four herbal extracts were selected based on the results from initial screening studies, and 
their effects were further confirmed using three different concentrations, 3-6 wells per 
group. Each follow-up experiment was performed four times. 
2.4 Cell detachment index (CDI) and lactate dehydrogenase (LDH) release assay 
For the screening studies, in vitro cytotoxicity at the end of 48 h treatment was assessed by 
phase-contrast microscopy using the same CDI criteria that we  reported before (Hu et al., 
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2009). In brief, CDI reflects cell monolayer disruption, including cell detachment from the 
adherent surface and disorganisation of cell monolayer. Scores of 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5 and 
4 represented an area of 0, 5%, 10%, 20%, 30%, 40%, 60%, 80% and 100%, respectively, of the 
total adherent surface not covered by cells. This method was used to approximate cytotoxicity, 
as well as to ensure the reliability of subsequent picro-Sirius red (PSR) staining results, which 
required minimum cell (and matrix) detachment and disruption of cell monolayer. For follow-
up studies, LDH release assay was used to assess in vitro cytotoxicity at the end of 48 h 
treatment. Fifty microlitre of supernatant from each well was collected and tested for LDH 
release according to the manufacturer's instructions (Promega, Southampton, UK). LDH 
release was measured using a Dynex Technologies MRX spectrophotometer (Prior Laboratory 
Supplies Ltd., East Sussex, UK), at optical density (OD) value of 490 nm. 
2.5 Microscopic examination 
Microscopic examination was performed on a Nikon Eclipse TE2000-S microscope (Nikon 
Instruments Europe B.V., The Netherlands). Bright-field and phase-contrast images were 
captured with a DXM1200F Nikon digital camera (Nikon UK Limited, Surrey, UK) and 
processed with Adobe Photoshop (Adobe System Europe Ltd., London, UK). 
2.6 PSR staining and spectrophotometric analysis 
Total collagen accumulation was assessed qualitatively by microscopic examination of PSR-
stained cells and quantitatively by spectrophotometric analysis of PSR staining. After CDI 
determination and conditioned medium collected for LDH release assay, cell monolayer in 96-
well plates were fixed in ice-cold methanol (200 µl per well) overnight at –20 C. Cells were 
carefully washed twice (5 min each) with 1x phosphate buffered saline (PBS, 200 µl per well) 
and then stained with 0.1% w/v PSR solution (200 µl per well, Sigma-Aldrich) at room 
temperature for 46 h. The staining solution was then removed and excessive PSR stain was 
carefully washed off with 0.1% v/v acetic acid (200 µl per well, VWR International Ltd, 
Lutterworth, UK) three times (5 min each). The stained wells were left to air dried for 2448 h. 
PSR stain was then observed under bright-field microscopy and microscopic pictures were 
taken. Finally, PSR stain was eluted in 0.1 N NaOH (200 µl per well) on a rocking platform at 
room temperature for 1 h. The plate was then subjected to spectrophotometric analysis of OD 
at 540 nm on a Dynex Technologies MRX spectrophotometer (Hu et al., 2009). 
2.7 PPAR, PPAR/ and PPAR agonistic activities of Shiliuhua extract and effect of 
Shiliuhua extract in the presence of PPAR antagonists  
We commissioned Tebu-bio Laboratories, Le Perray en Yvelines, France, to perform a pilot 
test on Shiliuhua extract for its isotype-specific PPAR activation. In brief, the assay was 
carried out in vitro in three HeLa cell lines stably expressing a chimeric protein containing 
the yeast transactivator GAL4 DNA binding domain fused to ligand binding domain 
regions of human PPAR, PPAR/ or PPAR, and a luciferase reporter gene driven by a 
pentamer of the GAL4 recognition sequence in front of the β-globin promoter (Seimandi et 
al., 2005).  The PPAR reporter cell lines were seeded in a 96-well plate in triplicates, and 
treated with 40 g/ml Shiliuhua extract, or an equal volume of DMSO as negative control, 
for 24 h. Luciferase activity was determined with a luminometer and relative light units 
(RLU) were recorded. Three independent experiments were performed and the fold changes 
of RLU were normalised to the mean of negative control. 
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The effect of PPAR antagonism on Shiliuhua extract treatment was assessed following the 
protocol as described in sections 2.3-2.6. Cells were treated with 40 g/ml Shiliuhua extract 
with and without PPAR antagonist, GW6471 (0.01-10 M), PPAR/ antagonist, GSK0660 
(0.001-1 M), or PPAR antagonist, T0070907 (0.1-25 μM). Three independent biological 
experiments were performed, 3-6 wells per group.  
2.8 Statistical analysis 
Results of PSR and LDH OD values were expressed as mean  SEM unless stated otherwise. 
Statistical differences were computed with Prism 4.0 (GraphPad Software, San Diego, CA, 
USA), by one-way analysis of variance and Dunnett post test for comparison between a 
control group and all other groups; for PPAR reporter activity, one-tail paired t test was 
performed on log-transformed fold changes. p<0.05 was regarded as statistically significant. 
3. Results 
3.1 Initial screening 
The screening results of CMM extracts were summarised in Table 2. Anti-fibrotic and pro-
fibrotic effects were defined as PSR OD values significantly lower and higher than that of 
TGF-1-treated group, respectively; cytotoxicity was defined as CDI significantly higher 
than that of TGF-1-treated group. Doses at which extracts exhibited reproducible effects 
were indicated in the table. The CMMs were categorised into four groups, i.e., eight in 
Group A showed in vitro anti-fibrotic activities; three in Group B showed pro-fibrotic 
activities; six in Group C showed prominent cytotoxicity; 11 in Group D did not have 
profound effects on total collagen accumulation nor integrity of cell monolayer. In Group A, 
Liedang, Meiguiqie and Gusuibu extracts were well-tolerated agents with anti-fibrotic 
activities noted within the range of 80-200 µg/ml; extracts of Shiliuhua, Baibeiyegen, 
Jixueteng, Moyao and Lingzhi showed anti-fibrotic effects at concentrations ranging from 
1080 µg/ml, beyond which cytotoxicity was noted. In Group B, Chuanwutou showed a 
pro-fibrotic effect at concentrations as low as 20 µg/ml whereas pro-fibrotic effect of 
Dangshen and Yimucao were observed only at higher concentrations (160200 µg/ml). 
3.2 Follow-up studies 
Based on the initial screening results, Shiliuhua (SLH), Liedang (LD), Meiguiqie (MGQ) and 
Chuanwutou (CWT) extracts were selected for follow-up studies in view of their minimum 
CDI changes indicating low cytotoxicity, and the results are shown in Fig. 1. In contrast to 
SLH, LD and MGQ extracts, which showed varying degrees of in vitro anti-fibrotic effects, 
CWT extract exhibited a marked pro-fibrotic effect. Representative effects of SLH, LD, MGQ 
and CWT extracts on PSR staining, relative PSR OD values and LDH release are shown in 
Fig. 2 and Fig. 3. 
3.3 Activation of PPARs by SLH extract 
As SLH extract is one of the CMM extracts with the most potent in vitro anti-fibrotic activity 
and it was previously reported to interfere with the PPAR signalling pathway (Li et al., 
2008), we hypothesised that the anti-fibrotic effect of SLH extract was at least in part 
mediated by activation of one or more PPAR receptors. Indeed, SLH extract induced PPAR- 
and PPAR-mediated reporter activity; it also marginally activates PPAR/ but the induction 
of reporter activity was just above the threshold of significance (p=0.066) (Fig. 4a). In order to 
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determine if the agonistic effect of SLH extract has an impact on TGF-1-induced fibrogenesis, 
cells were treated with SLH extract and individual PPAR antagonists. PPAR/ antagonist, 
GSK0660 (IC50 160 nM) (Shearer et al., 2008), did not affect the anti-fibrotic activity of SLH 
extract at all concentrations tested (up to 6.25-fold higher than its IC50); PPAR antagonist, 
GW6471 (IC50 240 nM) (Xu et al., 2002), also did not show any significant effect at 
concentrations up to 4.2-fold of its IC50, but at 10 M (42-fold higher than its IC50), it did 
moderately suppress the anti-fibrotic activity of SLH extract; PPAR antagonist, T0070907 (IC50 
1 nM in inhibiting rosiglitazone binding to PPAR and 3.2-24.3 μM in inhibiting proliferation 
of different cancer cell lines) (Lee et al., 2002; Burton et al., 2007), did not show any significant 
effect at concentrations of 0.1, 1 and 10 μM, but further increased the anti-fibrotic effect of 
SLH extract at 25 μM (Fig. 4b). 
 
Group Pinyin name Anti-fibrotic or 
pro-fibrotic 
doses (g/ml) 
Changes at optimum 
doses compared to TGF-
1 treated group  
Cytotoxic doses 
(g/ml) 
A. Anti-fibrotic  Baibeiyegen 20-40 -81.4% (40 g/ml) 
-63.3% (20 g/ml) 
≥80 
Liedang 80-160 -61.2% (160 g/ml) 
-59.3% (80 g/ml) 
200 
Gusuibu 160-200 -36.8% (200 g/ml) 
-30.0% (160 g/ml) 
— 
Jixueteng 10-40 -75.0% (20 g/ml) 
-63.0% (10 g/ml) 
≥80 
Lingzhi 10-80 -34.9% (80 g/ml) 
-47.4% (40 g/ml) 
≥160 
Meiguiqie 160-200 -28.0% (200 g/ml) 
-21.0% (160 g/ml) 
— 
Moyao 10-40 -57.2% (40 g/ml) 
-67.9% (20 g/ml) 
≥80 
Shiliuhua 10-40 -78.0% (40 g/ml) 
-61.2% (20 g/ml) 
≥80 
B. Pro-fibrotic 
 
Chuanwutou ≥20 +90.2% (40 g/ml) 
+68.5% (20 g/ml) 
— 
Dangshen 200 +32.4% (200 g/ml) — 
Yimucao 160-200 +65.7% (200 g/ml) 
+53.9% (160 g/ml) 
— 
C. Cytotoxic Baihuasheshecao (≥80 g/ml), Ruxiang (≥10 g/ml), Sheputaogen (≥80 
g/ml), Tiannanxing (≥80 g/ml), Yinxingye (≥20 g/ml), Zhenzhumei (≥40 
g/ml).
D. Inert Baiguo, Ezhu, Gancao, Jiegeng, Maqianzi, Niuxi, Roucongrong, Sanleng, 
Taoren, Yanhusuo, Yinyanghuo. 
Table 2. Initial screening results of CMMs in TGF-1-induced in vitro fibrogenesis. Minus (-) 
and plus (+) percentages represent relative reduction and increase in TGF-1-induced PSR 
OD values, respectively. “—”: Cytotoxicity, assessed from CDI, was not significantly 
different from TGF-1-treated group at all concentrations tested (10-200 µg/ml). 
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Fig. 1. In vitro anti-fibrotic and pro-fibrotic effects of four selected extracts, Shiliuhua (SLH) 
(a), Liedang (LD) (b), Meiguiqie (MGQ) (c) and Chuanwutou (CWT) (d) at three selected 
concentrations. Shown here are relative PSR OD changes of four independent experiments. 
The CDI changes were minimum and not shown. The average PSR OD values of negative 
control group and TGF-1-treated group were normalised to 0 and 100%, respectively, and 
changes in percentage of herbal extract-treated groups were relative to the TGF-β1 only 
group. *, **: p<0.05 and p<0.01 vs TGF-1 only group. 
 
 
Fig. 2. Effects of Shiliuhua (SLH) and Liedang (LD) extracts on PSR staining (a), relative PSR 
OD values (b) and LDH release (c). Results in (b) and (c) shown here are in Mean ± SEM 
from one representative experiment, ** p<0.01 vs TGF-β1 only group, n=6 wells. The 
average PSR OD values of negative control group and TGF-1 only group were normalised 
to 0 and 100%, respectively, and changes in percentage of herbal extract-treated groups were 
relative to the TGF-β1 only group. 
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Fig. 3. Effects of Meiguiqie (MGQ) and Chuanwutou (CWT) extracts on PSR staining (a), 
relative PSR OD values (b) and LDH release (c). Results in (b) and (c) shown here are in 
Mean ± SEM from one representative experiment, *, ** p<0.05, p<0.01 vs TGF-β1 only group, 
n=6 wells. The average PSR OD values of negative control group and TGF-1 only group 
were normalised to 0 and 100%, respectively, and changes in percentage of herbal extract-
treated groups were relative to the TGF-β1 only group. 
 
 
Fig. 4. Regulation of PPAR, PPAR/ and PPAR activation by Shiliuhua (SLH) extract 
and effects of PPAR, PPAR/ and PPAR antagonists on the anti-fibrotic effect of SLH 
extract. a. Effects of SLH extract on PPAR, PPAR/ and PPAR activation, n=3 
independent biological experiments; b. effects of increasing doses of PPAR, PPAR/ and 
PPAR antagonists on the anti-fibrotic effect of SLH extract. ** p<0.01 vs control group, n=3 
independent biological experiments. Other statistical results are as indicated in the figures. 
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4. Discussion 
4.1 Knowledge-based discovery of anti-fibrotic activities from CMMs 
Further to the evidence-based approach that we used in our earlier screens (Hu et al., 2009), 
in which we selected CMMs that had been reported to reduce fibrotic lesions in vivo, we 
used a knowledge-based approach in this study, namely, to screen candidate CMMs that 
were believed to be beneficial in treating fibrotic diseases based on the theory and practice 
of TCM. Of the 28 CMM extracts examined, eight (28.5%) showed reproducible in vitro anti-
fibrotic activities, i.e., Baibeiyegen, Liedang, Gusuibu, Jixueteng, Lingzhi, Meiguiqie, Moyao 
and Shiliuhua. Identification of these CMMs with anti-fibrotic activities in vitro underscores 
their inflammation-independent activities to inhibit TGF-1-induced total collagen 
accumulation, perhaps through inhibiting TGF-1-specific signalling or common pathways 
of fibrogenesis. 
Among the eight CMM extracts with anti-fibrotic activities, Baibeiyegen (Zhao et al., 2002), 
Lingzhi (Lin et al., 2006; Wang et al., 2009; Wu et al., 2010), Meiguiqie (Liu et al., 2006), 
Moyao (Massoud et al., 2004) and Shiliuhua (Huang et al., 2005) have been reported anti-
fibrotic in animal models of liver fibrosis or in hepatic stellate cells; Gusuibu was one of the 
weakest and its effect on fibrosis has never been previously reported either in vivo or in vitro; 
Liedang has not been reported on its effect on fibrosis either, but the ethanolic extract of its 
closely related family member Boschniakia rossica (Cham. & Schltdl.) B. Fedtsch. has been 
reported to mitigate liver fibrosis in a rat model of dimethylnitrosamine-induced liver 
fibrosis (Piao et al., 2005); Jixueteng is used in some herbal formulae, such as 
Huangqijixuetengtang (Li et al., 2006; Li et al., 2007) and Herbal Compound 861 (also known 
as Fufangdanshenheji) (Wang 2000; Wang et al., 2008), which were reported to be anti-
fibrotic in patients and in vitro, but has never been reported as an individual anti-fibrotic 
herb. 
Although only a quarter of the selected CMMs showed anti-fibrotic activities in our model, 
we do not exclude the possibilities that some of these CMMs might have a favourable effect 
in treating fibrotic diseases by interfering with other factors e.g. inflammation, TGF-1 
production and activation, molecules upstream of TGF-1 signalling and TGF-1-
independent pro-fibrotic signalling pathways. Of note, CMMs which were identified as 
cytotoxic in the NRK-49F renal fibroblast model might be of therapeutic value in fibrotic 
diseases since loss of fibroblasts, the main producers of pathological matrices, may result in 
reduced ECM accumulation hence promoting regression of fibrosis. It is also worth 
reiterating that the results presented here were derived from extracts of CMMs in boiling 
80% ethanol. Different extraction methods, including extraction solutions and efficiency, 
might have different impact on in vitro activities of the materials. Nevertheless, it would be 
of particular interest to isolate compounds contained in the eight ethanolic CMM extracts 
with in vitro anti-fibrotic activities, and to further test individual compounds for their in vitro 
anti-fibrotic activities. 
4.2 In vitro anti-fibrotic activities and TCM categorisation of the CMMs  
CMMs are traditionally characterised based on their function, nature, taste and channel 
tropism. By focusing on functional groups of the selected CMMs, we found that four out of 
15 (27%) CMMs of “Huo Xue Hua Yu” group, two out of six (33%) CMMs of “Hua 
Tan“ group and three out of seven (43%) CMMs of “Bu Xu” group, had in vitro anti-fibrotic 
activities. In view that “Hua Tan” and “Bu Xu”groups had rarely been the focus of previous 
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evidence-based studies of anti-fibrotic CMMs, we consider our findings significant in 
guiding future studies of anti-fibrotic herbal medicines and in selecting therapeutic options 
in the clinic. However, due to the small sample numbers involved in this study, we do not 
intend to conclude that CMMs of certain functional groups have a higher chance of being 
anti-fibrotic than another. For example, results of Danshen, a drug in the “Huo Xue Hua 
Yu” group, was excluded from this project as it has been tested and reported elsewhere (Hu 
et al., 2009). In fact, Danshen is the most used herb in the 16 herbal formulae that showed in 
vitro anti-fibrotic activities (Hu et al., 2009). On the other hand, our results do not negate the 
fact that other functional groups of CMMs may possess anti-fibrotic activities. For example, 
Dahuang (root of Rheum palmatum L.) and Huangqin (root of Scutellaria baicalensis Georgi), 
both not in these three functional groups, had been previously reported to be anti-fibrotic 
and their activities had been confirmed in our earlier studies (Hu et al., 2009). 
4.3 Shiliuhua and PPAR 
In this study, Shiliuhua extract was one of the most potent CMMs in reducing TGF-1-
induced matrix accumulation. Extracts of Shiliuhua had been previously reported to activate 
PPAR and induce PPAR expression. We found that ethanolic extract of Shiliuhua 
significantly activated both PPAR and PPAR, which might account for its anti-fibrotic 
activity since agonists of PPAR (Toyama et al., 2004; Iglarz et al., 2003) and PPAR (Milam 
et al., 2008; Kawai et al., 2008; Iglarz et al., 2003) were previously reported to suppress 
fibrosis of liver, lung, heart and kidney. Contrary to our hypothesis, we found that the anti-
fibrotic activities of Shiliuhua extract can only be partially blocked by GW6471, a PPAR 
antagonist, at a dose 42-fold of its reported IC50. Since the dose of PPAR antagonists were 
selected based on their IC50 reported in other cell types, it is possible that the doses we 
employed were sub-optimal in blocking PPARs in NRK-49F renal fibroblast cells. More 
interestingly, T0070907, a PPAR antagonist, further increased the anti-fibrotic effect of 
shiliuhua extract when used at high dose (25 M). Thus, it appears that Shiliuhua extract can 
activate both PPAR and PPAR, but this property could not explain the anti-fibrotic 
activity of Shiliuhua in full. Further studies are required to elucidate the involvement of 
PPAR signalling pathway in anti-fibrotic activities of shiliuhua, for example to establish if 
these two PPAR isotypes have opposing functions in regulating fibrogenesis in renal 
fibroblasts in view that they did have opposing effects on monocyte chemotaxis in 
endometriosis (Hornung et al., 2001). 
4.4 In vitro pro-fibrotic activities observed in this project 
The in vitro pro-fibrotic activities of Chuanwutou, Dangshen and Yimucao deserve special 
attention. It rationalises pharmacovigilant studies to establish clinical relevance of these 
effects. Before clinical conclusions are drawn, it might be wise to avoid un-necessary, large-
dose and long-term use of these herbs, especially in patients prone to fibrotic diseases. This 
issue is important because Dangshen and Yimucao are commonly used in formulae for 
fibrotic diseases (Yao et al., 2003) and Chuanwutou is indicated for conditions such as 
osteoarthritis, muscular diseases and stroke that often are complicated by fibrosis as well. 
As CMMs are rarely used individually, it is important to explore if their pro-fibrotic 
activities could be antagonised or eliminated when used in formulae. Of note, Yimucao had 
been reported in animal models to induce nephrotoxicity, including renal fibrosis, but its 
toxicity was reduced when used in formulae (Sun et al., 2005a, 2005b).  
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Among the three pro-fibrotic herbs, Chuanwutou appeared to be the most potent. 
Chuanwutou has well-known toxic effects that are believed to be reduced through a special 
processing procedure known as “Paozhi” (Chan et al., 1994; Singhuber et al., 2009), but as 
far as we know, this is the first report linking Chuanwutou to potent pro-fibrotic activities. 
The Chuanwutou we examined in this project was a raw material that had not undergone 
any ”Paozhi” before ethanolic extraction. It is important to establish if the potent pro-fibrotic 
effect of this toxic herb could be reduced or even eliminated through traditional “Paozhi” 
and if this newly identified adverse effect contributes to any known clinical toxicity and 
adverse effects, in view that only processed Chuanwutou is allowed to be used in TCM 
practice according to the Chinese Pharmacopeia. 
Interestingly, while extract of Dangshen, the root of Codonopsis pilosula (Franch.) Nannf. was 
found pro-fibrotic in this study, pollen of the same plant had been previously reported to be 
effective in preventing carbon tetrachloride-induced liver damage including fibrosis (Xiao et 
al., 1989). Furthermore, Fuzi, the daughter roots of the same plant as Chuanwutou, is a 
CMM categorised into a different functional group. We examined Fuzi in our in vitro model 
but it did not show any pro-fibrotic, anti-fibrotic or apparent cytotoxicity (data not shown). 
Thus, different parts of the same plant might have different and even opposite effects in 
regulating fibrogenesis. 
5. Conclusion 
Among the 28 herbal and fungal materials tested, eight showed in vitro anti-fibrotic 
activities while another three, especially Chuanwutou, showed pro-fibrotic activities. These 
results warrant further prudent investigations of their potential translation into clinical 
efficacy and their adverse effects. 
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